Boston Scientific Corporation (BSX) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $46.92 (+0.35%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 17, 2026 | William Plovanic | Canaccord Genuity | $109.00 | +132.3% |
| Feb 6, 2026 | Lee Hambright | Bernstein | $112.00 | +138.7% |
| Feb 5, 2026 | William Plovanic | Canaccord Genuity | $112.00 | +138.7% |
| Feb 4, 2026 | Rick Wise | Stifel Nicolaus | $110.00 | +134.4% |
| Jan 9, 2026 | David Roman | Goldman Sachs | $112.00 | +138.7% |
| Dec 17, 2025 | William Plovanic | Canaccord Genuity | $131.00 | +179.2% |
| Oct 23, 2025 | Patrick Wood | Morgan Stanley | $130.00 | +177.0% |
| Oct 1, 2025 | Richard Newitter | Truist Financial | $129.00 | +174.9% |
| Sep 8, 2025 | Suraj Kalia | Oppenheimer | $125.00 | +166.4% |
| Jul 21, 2025 | Jayson Bedford | Raymond James | $121.00 | +157.9% |
| Jun 16, 2025 | Mike Kratky | Leerink Partners | $118.00 | +151.5% |
| Apr 24, 2025 | Richard Newitter | Truist Financial | $117.00 | +149.3% |
| Apr 23, 2025 | Marie Thibault | BTIG | $124.00 | +164.3% |
| Feb 3, 2025 | Matt O'Brien | Piper Sandler | $115.00 | +145.1% |
| Jan 2, 2025 | Vijay Kumar | Evercore ISI | $100.00 | +113.1% |
| Dec 30, 2024 | Marie Thibault | BTIG | $101.00 | +115.2% |
| Oct 24, 2024 | Shagun Singh | RBC Capital | $98.00 | +108.8% |
| Oct 24, 2024 | Kristen Stewart | C.L. King | $90.00 | +91.8% |
| Oct 21, 2024 | William Plovanic | Canaccord Genuity | $98.00 | +108.8% |
| Oct 18, 2024 | Rick Wise | Stifel Nicolaus | $100.00 | +113.1% |
Top Analysts Covering BSX
BSX vs Sector & Market
| Metric | BSX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.03 | 2.24 | 2.41 |
| Analyst Count | 60 | 8 | 19 |
| Target Upside | +76.5% | +11474.9% | +17.1% |
| P/E Ratio | 19.44 | 4.01 | 31.98 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $21.84B | $21.88B | $21.99B | 16 |
| 2027-03-31 | $5.64B | $5.69B | $5.74B | 11 |
| 2027-06-30 | $5.90B | $5.96B | $6.01B | 7 |
| 2027-09-30 | $5.94B | $6.00B | $6.05B | 8 |
| 2027-12-31 | $6.21B | $6.26B | $6.32B | 7 |
| 2028-03-31 | $6.04B | $6.10B | $6.15B | 6 |
| 2028-06-30 | $6.27B | $6.33B | $6.39B | 6 |
| 2028-09-30 | $6.33B | $6.39B | $6.45B | 11 |
| 2028-12-31 | $6.61B | $6.67B | $6.74B | 6 |
| 2029-12-31 | $28.67B | $29.01B | $29.60B | 15 |
| 2030-12-31 | $31.74B | $32.11B | $32.76B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.33 | $3.40 | $3.45 | 16 |
| 2027-03-31 | $0.88 | $0.89 | $0.90 | 10 |
| 2027-06-30 | $0.93 | $0.94 | $0.95 | 6 |
| 2027-09-30 | $0.94 | $0.96 | $0.97 | 7 |
| 2027-12-31 | $1.00 | $1.01 | $1.02 | 6 |
| 2028-03-31 | $0.99 | $1.00 | $1.01 | 7 |
| 2028-06-30 | $1.01 | $1.02 | $1.04 | 7 |
| 2028-09-30 | $1.03 | $1.05 | $1.06 | 12 |
| 2028-12-31 | $1.11 | $1.12 | $1.14 | 7 |
| 2029-12-31 | $4.79 | $4.87 | $4.99 | 2 |
| 2030-12-31 | $5.36 | $5.45 | $5.59 | 5 |
Frequently Asked Questions
What is the analyst consensus for BSX?
The consensus among 60 analysts covering Boston Scientific Corporation (BSX) is Buy with an average price target of $108.35.
What is the highest price target for BSX?
The highest price target for BSX is $132.00, set by John Eade at Argus Research on 2021-08-02.
What is the lowest price target for BSX?
The lowest price target for BSX is $47.00, set by Steven Lichtman at Oppenheimer on 2021-04-28.
How many analysts cover BSX?
60 analysts have issued ratings for Boston Scientific Corporation in the past 12 months.
Is BSX a buy or sell right now?
Based on 60 analyst ratings, BSX has a consensus rating of Buy (2.03/5) with a +76.5% upside to the consensus target of $108.35.
What are the earnings estimates for BSX?
Analysts estimate BSX will report EPS of $3.40 for the period ending 2026-12-31, with revenue estimated at $21.88B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.